Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical CoTAK +0.97%76 EV-to-EBITDA is 19.22 as of Aug. 06, 2026, which is 82% above its 10-year median of 10.57. GuruFocus rates TAK with a GF Score™ of 76/100 and a GF Value™ of $14.44 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 743 Drug Manufacturers companies, Takeda Pharmaceutical Co ranks worse than 66.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Takeda Pharmaceutical Co's enterprise value is $81,394 Mil.
Takeda Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $4,234 Mil. Therefore, Takeda Pharmaceutical Co's EV-to-EBITDA for today is 19.22.
The historical rank and industry rank for Takeda Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
TAK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.93 Med: 10.57 Max: 28.09
Current: 19.88
During the past 13 years, the highest EV-to-EBITDA of Takeda Pharmaceutical Co was 28.09. The lowest was 6.93. And the median was 10.57.
TAK's EV-to-EBITDA is ranked worse than 66.35% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs TAK: 19.88
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Takeda Pharmaceutical Co (NYSE:TAK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Takeda Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Takeda Pharmaceutical Co's share price for today is $16.72.
Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.338.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's EV-to-EBITDA falls into.
Takeda Pharmaceutical Co's current Enterprise Value is $81,394 Mil.
Takeda Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,234 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (TAK) has a EV-to-EBITDA of 19.22 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Takeda Pharmaceutical Co. This is 82% above median its historical median of 10.57. Over the past decade, Takeda Pharmaceutical Co's EV-to-EBITDA has ranged from 6.93 to 28.09. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #493 out of 743 companies in the Drug Manufacturers industry, placing it in the top 66.4%.
Is Takeda Pharmaceutical Co's EV-to-EBITDA too high?
Takeda Pharmaceutical Co's current EV-to-EBITDA of 19.22 is 82% above median its 10-year median of 10.57. Over the past 10 years, this metric has ranged from a low of 6.93 to a high of 28.09. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. Takeda Pharmaceutical Co's value of 19.22 is 47.2% above this industry median. Based on the distribution chart, Takeda Pharmaceutical Co ranks #493 out of 743 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Takeda Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #493 out of 743 companies for EV-to-EBITDA. This places Takeda Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. Takeda Pharmaceutical Co's value of 19.22 is 47.2% above this benchmark. Historically, Takeda Pharmaceutical Co's own EV-to-EBITDA has ranged from 6.93 to 28.09 over the past decade. While the company's 10-year median is 10.57 vs. the industry median of 13.06, Takeda Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takeda Pharmaceutical Co's current EV-to-EBITDA of 19.22 is 47.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Takeda Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takeda Pharmaceutical Co's current EV-to-EBITDA is 19.22, which is 82% above median its own 10-year median of 10.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.44, compared to a current price of $16.72 — trading 15.8% above its estimated fair value. The current EV-to-EBITDA is 19.22, which is 82% above median its 10-year median of 10.57 and 47.2% above the Drug Manufacturers industry median of 13.06. Takeda Pharmaceutical Co's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current EV-to-EBITDA is 19.22 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of $16.72 is trading 15.8% above its estimated GF Value™ of $14.44.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TAK:
EV-to-EBITDA: 19.22 (82% above median its 10-year median of 10.57)
GF Value™: $14.44 vs. price of $16.72 (15.8% above fair value)
Industry Position: 47.2% above the Drug Manufacturers median (#493 of 743)
No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
76GF Score
Get the complete analysis for TAK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TAK has been successfully added to your 
